Abstract

Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4

Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio

Issue: Jul/Aug 2017 - Volume 21, Number 4

Page(s): 339-346

Download in electronic PDF format for $75
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 1
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 2
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 3
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 4
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 5
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 6
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 7
  • Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Page 8

Abstract

The objective of this study was to evaluate the stability of 7 commonly used active pharmaceutical ingredients compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend SF PH4): acetazolamide 25.0 mg/mL, baclofen 10.0 mg/mL, dipyridamole 10.0 mg/mL, mebeverine hydrochloride 10.0 mg/mL, propylthiouracil 5.0 mg/mL, quinidine sulfate 10.0 mg/mL, and topiramate 5.0 mg/mL. All suspensions were stored both at controlled refrigerated (2°C to 8°C) and room temperature (20°C to 25°C). Stability was assessed by measuring the percentage recovery at varying time points throughout a 90-day period. Active pharmaceutical ingredient quantification was performed by ultraviolet (UV) high-performance liquid chromatography, via a stability-indicating method. Given the percentage of recovery of the active pharmaceutical ingredients within the suspensions, the beyond-use date of the final products (active pharmaceutical ingredient + vehicle) was at least 90 days for all suspensions with regards to both temperatures. This suggests that SyrSpend SF PH4 is suitable for compounding active pharmaceutical ingredients from different pharmacological classes.

Related Keywords

  • acetazolamide
  • carbonic anhydrase inhibitor
  • baclofen
  • skeletal muscle relaxant
  • dipyridamole
  • adenosine reuptake inhibitor
  • mebeverine hydrochloride
  • smooth muscle relaxant
  • propylthiouracil
  • thiourea antithyroid
  • quinidine sulfate
  • class I anti-arrhythmic agent
  • topiramate
  • sulfamate
  • migraine
  • storage
  • stability-indicating assay
  • compatibility studies
  • physical stability
  • chemical stability

Related Categories

  • EXCIPIENTS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jul/Aug 2017
Pg. 339-346
Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4
Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Nov/Dec 2018
Pg. 516-526
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
May/Jun 2020
Pg. 224
Baclofen 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 130
Acetazolamide 25 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 136
Quinidine Sulfate 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Nov/Dec 2010
Pg. 512
Amitriptyline Hydrochloride 2%, Baclofen 5%, Ketamine Hydrochloride 5%, Ketoprofen 10% in Pluronic Lecithin Organogel
Author(s): Allen Loyd V Jr
May/Jun 2017
Pg. 234
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 136
Ketoprofen 10%, Baclofen 2%, Cyclobenzaprine Hydrochloride 2%, Lidocaine 2% in Lipopen Ultra Cream Base
Author(s): Allen Loyd V Jr
May/Jun 2019
Pg. 234
Mebeverine Hydrochloride 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
May/Jun 2012
Pg. 238
Acetazolamide 100-mg/mL Injection
Author(s): Allen Loyd V Jr
Sep/Oct 2021
Pg. 412
Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2024
Pg. 135
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Author(s): Allen Loyd V Jr
Sep/Oct 2019
Pg. 408
Dipyridamole 10 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jul/Aug 2020
Pg. 327-336
Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
May/Jun 2016
Pg. 231
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 135
Propylthiouracil 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 138
Topiramate 5 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Mar/Apr 2020
Pg. 156-162
Physicochemical Stability of Ternary Mixtures of Sufentanil, Baclofen, and Ropivacaine in Polypropylene Syringes for Intrathecal Analgesia
Author(s): Sorrieul Jérémy, Robert Julien, Chapel Fanny, Gossye Thomas, Devys Catherine
May/Jun 2020
Pg. 252-262
Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Nov/Dec 2018
Pg. 493
Diltiazem Hydrochloride 12 mg/mL in SyrSpend SF pH4 Oral Suspension
Author(s): Allen Loyd V Jr